EUVIMEDOpdag EUVIMED
EUVIMED · CrossrefJournal

Molecules

ISSN 1420-3049 · MDPI AG

Frequent topics

Fe3O4 nanoparticlesamyloid aggregation inhibitionhybrid nanocompositesneurodegenerative diseases

Latest articles

  1. Intercellular Junctions as Targets of Metal Toxicity: A Narrative Review

    Patricia Bizarro-Nevares, Teresa I. Fortoul, Nelly López-Valdez, José Ángel Salgado-Hernández, Sofía Mendiola-Reyes, María Eugenia Cervantes-Valencia, Guadalupe Morales-Ricardes, Brenda Casarrubias-Tabarez, Gabriela Guerrero-Palomo, Adriana González-Villalva, Lorena Cevallos, Paulina Reséndiz Ramírez, Marcela Rojas-Lemus, Nancy Villafaña-Guillén, Madeline Ixchel Linares Soriano, Armando Zepeda-Rodríguez, Martha Luz Ustarroz-Cano

    Published: 2026-11-19DOI: 10.3390/molecules31224200

  2. Valorization of Canola (Brassica napus L.) and Sunflower (Helianthus annuus L.) By-Products for Sustainable Protein Extraction: Impact of Emerging Technologies on Physicochemical, Functional, and Structural Properties

    Nitzia Thalía Flores-Jiménez, José Armando Ulloa, Judith Esmeralda Urías-Silvas, Petra Rosas-Ulloa, Kevin Ulises López-Mártir, José Carmen Ramírez-Ramírez, Ranferi Gutiérrez-Leyva, Yessica Silva-Carrillo, Blanca Estela Ulloa-Rangel

    Published: 2026-11-19DOI: 10.3390/molecules31224208

Volumes

2026 · 4,0802025 · 4,8302024 · 5,9682023 · 8,0572022 · 9,1442021 · 7,7912020 · 6,0602019 · 4,6672018 · 3,4462017 · 2,2782016 · 1,7702015 · 1,3852014 · 1,3022013 · 1,0122012 · 1,0662011 · 7642010 · 6602009 · 4162008 · 2582007 · 2252006 · 1082005 · 1542004 · 1132003 · 932002 · 1022001 · 1912000 · 3541999 · 781998 · 811997 · 1051996 · 16

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.